ABSTRACT
AIMS: In response to the COVID-19 pandemic, the UK was placed under strict lockdown measures on 23 March 2020. The aim of this study was to quantify the effects on physical activity (PA) levels using data from the prospective Triage-HF Plus Evaluation study. METHODS: This study represents a cohort of adult patients with implanted cardiac devices capable of measuring activity by embedded accelerometery via a remote monitoring platform. Activity data were available for the 4 weeks pre-implementation and post implementation of 'stay at home' lockdown measures in the form of 'minutes active per day' (min/day). RESULTS: Data were analysed for 311 patients (77.2% men, mean age 68.8, frailty 55.9%. 92.2% established heart failure (HF) diagnosis, of these 51.2% New York Heart Association II), with comorbidities representative of a real-world cohort.Post-lockdown, a significant reduction in median PA equating to 20.8 active min/day was seen. The reduction was uniform with a slightly more pronounced drop in PA for women, but no statistically significant difference with respect to age, body mass index, frailty or device type. Activity dropped in the immediate 2-week period post-lockdown, but steadily returned thereafter. Median activity week 4 weeks post-lockdown remained significantly lower than 4 weeks pre-lockdown (p≤0.001). CONCLUSIONS: In a population of predominantly HF patients with cardiac devices, activity reduced by approximately 20 min active per day in the immediate aftermath of strict COVID-19 lockdown measures. TRIAL REGISTRATION NUMBER: NCT04177199.
Subject(s)
Accelerometry , COVID-19 , Communicable Disease Control , Heart Failure , Monitoring, Physiologic , Physical Distancing , Telemedicine , Accelerometry/instrumentation , Accelerometry/methods , Accelerometry/statistics & numerical data , Activities of Daily Living , Aged , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control/methods , Communicable Disease Control/statistics & numerical data , Exercise , Female , Heart Failure/diagnosis , Heart Failure/epidemiology , Humans , Male , Monitoring, Physiologic/instrumentation , Monitoring, Physiologic/methods , Monitoring, Physiologic/statistics & numerical data , SARS-CoV-2 , Telemedicine/instrumentation , Telemedicine/methods , Telemedicine/statistics & numerical data , United Kingdom/epidemiology , Wearable Electronic DevicesABSTRACT
PURPOSE: As second and third waves of the COVID-19 pandemic challenge healthcare in North America and Europe once again, we analyze the impact of the first wave on routine elective cardiovascular care, and the differential COVID risk emerging within our patient groups and staff. PERSPECTIVE: We describe the need to sustainably resume, and temporarily expand, routine elective cardiac services in the face of resurgent COVID-19. Some, but not all, cardiac patient groups are particularly vulnerable to adverse outcomes following COVID-19 infection. We explore mitigation measures at the institutional level to increase resilience within cardiac services to enable them to operate deep into subsequent waves of COVID infection which place unprecedented demands on intensive care infrastructure. As measures to eradicate the virus appear to have failed in many countries, and vaccine roll-out will take many months we take the view that the threat imposed by endemic COVID-19 alters the way elective procedural care should be offered to cardiovascular patients. CONCLUSION: Our patients are at definite risk from their cardiovascular disease, and a return to suspension of proven prognostic interventional treatments on an elective basis - the default for the first wave - must be avoided at all costs.
Subject(s)
Betacoronavirus , Coronavirus Infections/therapy , Health Personnel , Occupational Exposure/prevention & control , Percutaneous Coronary Intervention , Pneumonia, Viral/therapy , ST Elevation Myocardial Infarction/therapy , COVID-19 , Coronavirus Infections/epidemiology , Fibrinolytic Agents/therapeutic use , Health Personnel/standards , Humans , Occupational Exposure/adverse effects , Pandemics , Percutaneous Coronary Intervention/adverse effects , Pneumonia, Viral/epidemiology , SARS-CoV-2 , ST Elevation Myocardial Infarction/epidemiologyABSTRACT
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious, carries significant morbidity and mortality, and has rapidly resulted in strained health care system and hospital resources. In addition to patient-related care concerns in infected individuals, focus must also relate to diminishing community spread, protection of staff, case selection, and concentration of resources. The current document based on available data and consensus opinion addresses appropriate catheterization laboratory preparedness for treating these patients, including procedure-room readiness to minimize external contamination, safe donning and doffing of personal protective equipment (PPE) to eliminate risk to staff, and staffing algorithms to minimize exposure and maximize team availability. Case selection and management of both emergent and urgent procedures are discussed in detail, including procedures that may be safely deferred or performed bedside.